Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Codatta Codatta +16.38%
#8 Enso Enso +16.32%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Classifica tra le azioni #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Prezzo delle azioni
$0.07600875
Ultima sincronizzazione: 2024-11-20
Capitalizzazione di mercato
$2.06M
Variazione (1 giorno)
-0.51%
Variazione (1 anno)
0.00%
Paese
FR
Scambia Quantum Genomics S.A. (ALQGC)

Categoria

Healthcare
Rapporto P/S per Quantum Genomics S.A. (ALQGC)
Rapporto P/S al August 2026 TTM: 499.95K
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Quantum Genomics S.A., il rapporto P/S attuale (TTM) è 499.95K. Alla fine del 2023, era pari a 186.65.
Storico del rapporto P/S per Quantum Genomics S.A. da 2009 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 499.95K -0.53%
2024 502.59K 269,175.26%
2023 186.65 11,422.08%
2022 1.62 -95.60%
2021 36.83 -32.65%
2020 54.68 39.21%
2019 39.28 -99.83%
2018 22.77K 0.00%
2017 0.00 0.00%
2016 0.00 -100.00%
2015 406.74 397.85%
2014 81.70 -94.18%
2013 1.40K 15.20%
2012 1.22K 290.81%
2011 311.74 0.00%
2010 311.74 -14.29%
2009 363.69 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -100.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -100.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -100.00%
BE